Affinity Asset Advisors’s MBX Biosciences MBX Stock Holding History

Affinity Asset Advisors’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.14M	Sell	75,000 -75,000	-50%	-$2.62M	0.19%	85
2026 Q1	$4.48M	Sell	150,000 -100,000	-40%	-$3.4M	0.23%	73
2025 Q4	$7.88M	Buy	250,000 +85,000	+52%	+$2.06M	0.45%	51
2025 Q3	$2.89M	Buy	+165,000	New	+$2.21M	0.25%	65
2025 Q2	–	Sell	-175,000	Closed	-$1.29M	–	118
2025 Q1	$1.29M	Buy	+175,000	New	+$1.85M	0.12%	76

Other funds holding MBX

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Affinity Asset Advisors's MBX Position: Q2 2026 in Review

Affinity Asset Advisors reduced its MBX Biosciences (MBX) stake by 50% in Q2 2026, selling an estimated $2.62M and leaving 75,000 shares worth $4.14M. The position accounts for 0.19% of the portfolio, ranked #85.

Affinity Asset Advisors first reported a position in MBX in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.88M in Q4 2025. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

Affinity Asset Advisors held 75,000 shares of MBX Biosciences worth $4.14M as of Q2 2026.
Affinity Asset Advisors sold 75,000 MBX Biosciences shares in Q2 2026, an estimated $2.62M.
MBX Biosciences made up 0.19% of Affinity Asset Advisors's portfolio in Q2 2026, its #85 holding.
Affinity Asset Advisors first reported a position in MBX Biosciences in Q1 2025 and has held it in 5 quarters since.
Affinity Asset Advisors's MBX Biosciences position peaked at $7.88M in Q4 2025.
172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.